Cellectar Biosciences Inc (CLRB)
3.385
-0.04
(-1.02%)
USD |
NASDAQ |
May 06, 15:05
Cellectar Biosciences PS Ratio
PS Ratio Chart
Historical PS Ratio Data
| Date | Value |
|---|---|
| March 28, 2024 | 660.18 |
| March 27, 2024 | 602.95 |
| March 26, 2024 | 638.62 |
| March 25, 2024 | 641.93 |
| March 22, 2024 | 671.79 |
| March 21, 2024 | 641.93 |
| March 20, 2024 | 618.71 |
| March 19, 2024 | 627.00 |
| March 18, 2024 | 555.68 |
| March 15, 2024 | 577.24 |
| March 14, 2024 | 560.65 |
| March 13, 2024 | 587.19 |
| March 12, 2024 | 602.12 |
| March 11, 2024 | 625.35 |
| March 08, 2024 | 663.50 |
| March 07, 2024 | 675.11 |
| March 06, 2024 | 663.50 |
| March 05, 2024 | 671.79 |
| March 04, 2024 | 703.31 |
| March 01, 2024 | 696.67 |
| February 29, 2024 | 650.23 |
| February 28, 2024 | 653.54 |
| February 27, 2024 | 643.59 |
| February 26, 2024 | 578.90 |
| February 23, 2024 | 554.02 |
| Date | Value |
|---|---|
| February 22, 2024 | 555.68 |
| February 21, 2024 | 543.24 |
| February 20, 2024 | 545.73 |
| February 16, 2024 | 571.44 |
| February 15, 2024 | 595.49 |
| February 14, 2024 | 580.56 |
| February 13, 2024 | 562.31 |
| February 12, 2024 | 580.56 |
| February 09, 2024 | 580.56 |
| February 08, 2024 | 582.22 |
| February 07, 2024 | 585.54 |
| February 06, 2024 | 588.85 |
| February 05, 2024 | 567.29 |
| February 02, 2024 | 623.69 |
| February 01, 2024 | 651.89 |
| January 31, 2024 | 648.57 |
| January 30, 2024 | 658.52 |
| January 29, 2024 | 698.33 |
| January 26, 2024 | 622.03 |
| January 25, 2024 | 595.49 |
| January 24, 2024 | 557.34 |
| January 23, 2024 | 612.08 |
| January 22, 2024 | 603.78 |
| January 19, 2024 | 577.24 |
| January 18, 2024 | 587.19 |
Price to Sales Ratio Definition
The Price to Sales Ratio (PS Ratio) is calculated by taking the stock price / revenue per share (ttm). This metric is considered a valuation metric that confirms whether the sales of a company justifies the stock price. There isn't necesarily an optimum PS ratio, since different industries will have different ranges of PS Ratios. Because of this, PS Ratio is great to evaluate from a relative standpoint with other similar companies. PS Ratio might also be a handy metric for companies that are not profitable yet, since they might be valued moreso by their overall sales and potential of becoming profitable in the future.
PS Ratio Range, Past 5 Years
91.02
Minimum
May 20 2019
728.04
Maximum
Jun 03 2021
324.72
Average
277.75
Median
PS Ratio Benchmarks
| Perspective Therapeutics Inc | -- |
| Eli Lilly and Co | 19.24 |
| Actinium Pharmaceuticals Inc | -- |
| Bristol-Myers Squibb Co | 1.983 |
| Altimmune Inc | 916.66 |
PS Ratio Related Metrics
| Price | 3.385 |
| Earnings Yield | -91.58% |
| Market Cap | 109.20M |